Curis, Inc. is a biotechnology company focused on the development of therapeutics for the treatment of cancer. The Company’s drug candidates include CA-4948 and CI-8993. CA-4948 is an orally available small-molecule inhibitor of Interleukin-I receptor-associated kinase 4, which is undergoing testing in a Phase I open-label dose escalating clinical trial in patients with non-Hodgkin lymphomas. It is also conducting a Phase I open-label, single-arm dose escalating trial in patients with acute myeloid leukemia, and myelodysplastic syndromes. CI-8993 is a monoclonal antibody designed to antagonize the V-domain Ig suppressor of the T cell activation signaling pathway. The Company initiated a Phase Ia/Ib trial of CI-8993 in patients with solid tumors. The Company’s products pipeline includes Fimepinostat, CA-170, CA-327, and PD1/TIM3 Program.